Upjohn/Chugai
Executive Summary
EPO and G-CSF will be the first products developed and marketed under a reported U.S. joint venture between the two firms. Chugai, which has licensed exclusive U.S. rights to the two recombinant products from Genetics Institute, will own 55% of the proposed corporation and Upjohn the remaining 45%. Chugai will license products to the joint venture and Upjohn will be the exclusive distributor for the first seven years after launch of the initial product.